As a preeminent contract antibody development company, Creative Biolabs offers high-quality in vitro diagnostic (IVD) antibody & immunoassay development services targeting a wide range of biomarkers, such as the Very Late Antigen-4 (VLA-4) protein. We are committed to providing the highest quality of custom services and products at the most reasonable prices.
Integrin is a type of the cell surface receptors expressed by almost all the cell types. In general, the integrin family can mediate cellular contacts to the extracellular matrix (ECM), other cells, and the elements of the plasma. All the integrins consist of noncovalently linked α and β subunits and each of the subunits can be comprised of a large extracellular domain, a single-spanning transmembrane domain, and a short cytoplasmic tail. The expression pattern of integrins changes during tumor growth, metastasis, and angiogenesis. As a member of the integrin family, VLA-4 is a transmembrane noncovalent heterodimer composed of CD49d (α4) and CD29 (β1). It has been found that VLA-4 is widely distributed in the hematopoietic cells and can bind to vascular cellular adhesion molecular 1 (VCAM-1), fibronectin, and osteopontin. It has been reported that the overexpression of VLA-4 can be detected in numerous cancer types and therefore has been served as the potential therapeutic target.
Fig.1 VLA-4 activation in integrin signaling pathways in B cells.1
Melanoma is one of the most common cancers in the world which always derived from the epidermal melanocytes. As the patients with primary melanoma can be cured by surgical resection, the diagnosis of melanoma might me much important and it is urgent to discover the IVD antibodies against the biomarkers. Some studies have shown that in the malignant melanoma cells, VLA-4 is used to adhere to the endothelium cells via binding to the ligand VCAM-1 and promote the transmigration and metastasis. It has also been reported that the increased expression of the VLA-4 in human melanoma can be associated with the tumor progression and contribute to inflammation-dependent metastasis. In this case, VLA-4 has been served as the great biomarker and the potential therapeutic target for melanoma.
Creative Biolabs provides customized services to biotech companies and academic researchers for their needs in developing diagnostic antibodies & immunoassays of various formats, including lateral flow assay, ELISA, latex-based assays, etc. With the successful completion of numerous projects, Creative Biolabs is confident in providing services and products of the best quality. Our services cover different stages of the immunoassay development process, including but not limited to:
Please feel free to contact us for more information and discuss your project needs.
Reference
For Research Use Only.
